Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:22AM EDT. Market open.
| Previous close | 138.97 |
| Open | 139.37 |
| Bid | 138.09 x 100 |
| Ask | 138.57 x 200 |
| Day's range | 137.68 - 139.37 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 885,569 |
| Market cap | 13.937B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 56.10 |
| EPS (TTM) | 2.47 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 153.29 |
Investor's Business DailyDoes Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?
Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine.
ZacksNeurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition.
© 2024 Yahoo. All rights reserved.